Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, metabolic/diabetes). He explains how AI is ...

https://www.thestreet.com/retirement/from-seed-to-sale-what-vcs-want-in-biotech-startups

#thestreet